Joel E Gallant

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi HIV counseling, testing, and referral
    Joel E Gallant
    Garey Lambert Research Center, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Am Fam Physician 70:295-302. 2004
  2. ncbi Antiretroviral therapy in resource-limited settings: is there still a role for stavudine?
    Joel E Gallant
    Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Antivir Ther 17:1507-9. 2012
  3. ncbi Essential components of effective HIV care: a policy paper of the HIV Medicine Association of the Infectious Diseases Society of America and the Ryan White Medical Providers Coalition
    Joel E Gallant
    Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
    Clin Infect Dis 53:1043-50. 2011
  4. ncbi The ideal nucleoside/nucleotide backbone
    Joel E Gallant
    Johns Hopkins University School of Medicine, Division of Infectious Diseases, Baltimore, MD 21287, USA
    J Acquir Immune Defic Syndr 37:S44-51. 2004
  5. ncbi Tenofovir disoproxil fumarate (Viread) for the treatment of HIV infection
    Joel E Gallant
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, 1830 E Monument St 443, Baltimore, MD 21287, USA
    Expert Rev Anti Infect Ther 1:415-22. 2003
  6. ncbi Protease-inhibitor boosting in the treatment-experienced patient
    Joel E Gallant
    Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    AIDS Rev 6:226-33. 2004
  7. ncbi Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment
    Joel E Gallant
    The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Clin Infect Dis 40:1194-8. 2005
  8. ncbi Approach to the treatment-experienced patient
    Joel E Gallant
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Curr HIV/AIDS Rep 2:83-9. 2005
  9. ncbi Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects
    Joel E Gallant
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    J Infect Dis 192:1921-30. 2005
  10. ncbi Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV
    Joel E Gallant
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    N Engl J Med 354:251-60. 2006

Detail Information

Publications82

  1. ncbi HIV counseling, testing, and referral
    Joel E Gallant
    Garey Lambert Research Center, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Am Fam Physician 70:295-302. 2004
    ....
  2. ncbi Antiretroviral therapy in resource-limited settings: is there still a role for stavudine?
    Joel E Gallant
    Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Antivir Ther 17:1507-9. 2012
    ..The goal in resource-limited settings should be to move away from use of thymidine analogues in first-line regimens...
  3. ncbi Essential components of effective HIV care: a policy paper of the HIV Medicine Association of the Infectious Diseases Society of America and the Ryan White Medical Providers Coalition
    Joel E Gallant
    Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
    Clin Infect Dis 53:1043-50. 2011
    ....
  4. ncbi The ideal nucleoside/nucleotide backbone
    Joel E Gallant
    Johns Hopkins University School of Medicine, Division of Infectious Diseases, Baltimore, MD 21287, USA
    J Acquir Immune Defic Syndr 37:S44-51. 2004
    ..Practical strategies are offered for implementing contemporary regimens in settings outside clinical trials...
  5. ncbi Tenofovir disoproxil fumarate (Viread) for the treatment of HIV infection
    Joel E Gallant
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, 1830 E Monument St 443, Baltimore, MD 21287, USA
    Expert Rev Anti Infect Ther 1:415-22. 2003
    ..Since its approval in October 2001, tenofovir disoproxil fumarate has quickly become a widely used component of antiretroviral regimens for both treatment-naive and -experienced patients...
  6. ncbi Protease-inhibitor boosting in the treatment-experienced patient
    Joel E Gallant
    Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    AIDS Rev 6:226-33. 2004
    ..This article reviews the principles of PI boosting, its advantages and disadvantages, and the clinical experience with this strategy in treatment-experienced populations...
  7. ncbi Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment
    Joel E Gallant
    The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Clin Infect Dis 40:1194-8. 2005
    ..Other associations included a lower CD4 cell count, decreased renal function at baseline, and diabetes. The declines were modest and did not lead to greater rates of discontinuation of therapy...
  8. ncbi Approach to the treatment-experienced patient
    Joel E Gallant
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Curr HIV/AIDS Rep 2:83-9. 2005
    ..Clinicians caring for such patients must balance the benefit of slower progression associated with continued therapy against the risk of increasing drug resistance and loss of future treatment options...
  9. ncbi Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects
    Joel E Gallant
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    J Infect Dis 192:1921-30. 2005
    ..Antiretroviral combinations that reduce the number of pills and dosing frequency have the potential to simplify therapy. We compared 2 regimens dosed as 2 pills once daily...
  10. ncbi Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV
    Joel E Gallant
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    N Engl J Med 354:251-60. 2006
    ..Durable suppression of replication of the human immunodeficiency virus (HIV) depends on the use of potent, well-tolerated antiretroviral regimens to which patients can easily adhere...
  11. ncbi Renal function with use of a tenofovir-containing initial antiretroviral regimen
    Joel E Gallant
    Department of Medicine, Johns Hopkins University School of Medicine, 1830 E Monument Street, Baltimore, MD 21205, USA
    AIDS 23:1971-5. 2009
    ....
  12. ncbi Approach to the treatment-experienced patient
    Joel E Gallant
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Infect Dis Clin North Am 21:85-102, viii-ix. 2007
    ..The management of treatment-experienced patients requires considerable expertise, especially now that patients with highly resistant virus can hope to achieve full virologic suppression...
  13. ncbi Should antiretroviral therapy be started earlier?
    Joel E Gallant
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, 1830 East Monument Street, Room 443, Baltimore, MD 21205, USA
    Curr HIV/AIDS Rep 4:53-9. 2007
    ..Therapy initiated early has better virologic and immunologic responses, is better tolerated, and is cost-effective. Recent developments and clinical data support a return to earlier initiation of therapy...
  14. ncbi What does the generalist need to know about HIV infection?
    Joel E Gallant
    Department of Medicine and Epidemiology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Adv Chronic Kidney Dis 17:5-18. 2010
    ..They should be able to recognize antiretroviral toxicity and should be aware of common drug-drug interactions involving antiretroviral agents...
  15. ncbi Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistance
    Joel E Gallant
    The Johns Hopkins University, Baltimore, MD, USA
    Antivir Ther 8:489-506. 2003
    ..This review summarizes research advances that further the understanding of nucleoside and nucleotide analogue resistance mutations, and their interplay...
  16. ncbi Tenofovir disoproxil fumarate
    Joel E Gallant
    Div of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Clin Infect Dis 37:944-50. 2003
    ..It is associated with more-favorable lipid profiles than stavudine and has not been associated with the mitochondrial toxicity attributed to other nucleoside analogues...
  17. ncbi Initial therapy of HIV infection
    Joel E Gallant
    Division of Infectious Diseases, The Johns Hopkins University School of Medicine, 1830 E Monument Street, Rm 443, Baltimore, MD 21287, USA
    J Clin Virol 25:317-33. 2002
    ..However, the rapid rate of virus mutation and subsequent emergence of drug-resistant HIV variants threaten the longer-term efficacy of HIV treatment. The initial regimen provides the greatest chance for lasting suppression of viral load...
  18. ncbi Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial
    Joel E Gallant
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    JAMA 292:191-201. 2004
    ..Tenofovir disoproxil fumarate (DF) is a once-daily nucleotide analogue reverse transcriptase inhibitor...
  19. ncbi The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients
    Joel E Gallant
    Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    AIDS 22:2155-63. 2008
    ..We analyzed the renal safety of TDF compared with thymidine analogue-containing (control) regimens through 144 weeks from two clinical trials in antiretroviral-naive HIV-infected patients...
  20. ncbi Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring
    Richard E Nettles
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Clin Infect Dis 42:1189-96. 2006
    ..High intraindividual pharmacokinetic variability may limit the utility of single measurements in therapeutic drug monitoring for some antiretroviral agents...
  21. ncbi Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis
    Anton L Pozniak
    Chelsea and Westminster Hospital, London, United Kingdom
    J Acquir Immune Defic Syndr 43:535-40. 2006
    ..7 vs. 5.5 kg; P < 0.001). CONCLUSION: Over 96 weeks, the combination of TDF, FTC, and EFV was superior to fixed-dose ZDV/3TC + EFV for achieving and maintaining an HIV RNA level <400 copies/mL and an increase in CD4 cells...
  22. ncbi Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART
    Richard E Nettles
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    JAMA 293:817-29. 2005
    ..CONCLUSION: Most blips in this population appear to represent random biological and statistical variation around mean HIV-1 levels below 50 copies/mL rather than clinically significant elevations in viremia...
  23. ncbi Antiretroviral therapy in the treatment of HIV-associated nephropathy
    Mohamed G Atta
    Department of Medicine, Division of Nephrology, Johns Hopkins University, 1830 East Monument Street, Baltimore, MD 21205, USA
    Nephrol Dial Transplant 21:2809-13. 2006
    ..This study was undertaken to further elucidate the potential benefit of ART in HIV-infected patients with documented HIVAN...
  24. ncbi Psychological distress and physical pain appear to have no short-term adverse impact on plasma HIV-1 RNA levels in patients on successful HAART
    Richard E Nettles
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 08543, USA
    HIV Clin Trials 6:262-71. 2005
    ....
  25. ncbi Host factors dictate control of viral replication in two HIV-1 controller/chronic progressor transmission pairs
    Robert W Buckheit
    Department of Medicine, Johns Hopkins University School of Medicine, 733 N Broadway, BRB 880, Baltimore, Maryland 21205, USA
    Nat Commun 3:716. 2012
    ..These data suggest that host factors have a dominant role in the control of HIV-1 infection, thus it may be possible to control fully pathogenic HIV-1 isolates with therapeutic vaccination...
  26. ncbi Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance
    Ajay K Sethi
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
    Clin Infect Dis 37:1112-8. 2003
    ..Clinicians and patients must set high adherence goals to avoid the development of resistance...
  27. ncbi High-risk behavior and potential transmission of drug-resistant HIV among injection drug users
    Ajay K Sethi
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
    J Acquir Immune Defic Syndr 35:503-10. 2004
    ..Participants were infected with drug-resistant HIV at 14% of visits when they were at higher risk of HIV transmission. Intensive risk reduction counseling is needed and must be integrated into routine HIV clinical care...
  28. ncbi Stability of the latent reservoir for HIV-1 in patients receiving valproic acid
    Janet D Siliciano
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA
    J Infect Dis 195:833-6. 2007
    ..We conclude that the clinical use of VA has no ancillary effect on the decay of the latent reservoir...
  29. ncbi Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells
    Justin R Bailey
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    J Virol 80:6441-57. 2006
    ..The sequences have been deposited in GenBank. The accession numbers are DQ 391282 to DQ 391351 (for env) and DQ 391352 to DQ 392955 (for RT)...
  30. ncbi Antiretroviral drug resistance and resistance testing
    Joel E Gallant
    The Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Top HIV Med 13:138-42. 2005
    ..As a result, it can be particularly useful in determining treatment options for treatment-experienced patients with multi-drug resistant virus. In many cases, there may be advantages to the use of both tests...
  31. ncbi The role of protective HCP5 and HLA-C associated polymorphisms in the control of HIV-1 replication in a subset of elite suppressors
    Yefei Han
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    AIDS 22:541-4. 2008
    ..These results suggest that some ES control viremia by mechanisms independent of the newly-identified genetic factors...
  32. ncbi Tenofovir disoproxil fumarate for the treatment of HIV infection
    Paul A Pham
    Johns Hopkins University School of Medicine, Division of Infectious Diseases, 1830 E Monument St 443, Baltimore, MD 21287, USA
    Expert Opin Drug Metab Toxicol 2:459-69. 2006
    ..Because of its demonstrated efficacy and favourable safety profile, tenofovir disoproxil fumarate has quickly become a favoured nucleoside component of antiretroviral regimens for both treatment-naive and -experienced patients...
  33. ncbi Bimodal virological response to antiretroviral therapy for HIV infection: an application using a mixture model with left censoring
    Xiuhong Li
    Room E7648, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
    J Epidemiol Community Health 60:811-8. 2006
    ..This data analysis overcomes limitations of measurement techniques of observations having values below detection limits and serves to characterise the dynamics of the virological response to therapies...
  34. ncbi Seronegative HIV-1 infection: a review of the literature
    Adam M Spivak
    Johns Hopkins School of Medicine, Division of Infectious Diseases, Baltimore, Maryland 21287, USA
    AIDS 24:1407-14. 2010
    ..We present a retrospective review of the clinical, virologic and immunologic characteristics of 25 persistently seronegative patients whose cases have been published to date and postulate a biologic mechanism for this phenomenon...
  35. ncbi Absolute CD4 vs. CD4 percentage for predicting the risk of opportunistic illness in HIV infection
    Kelly A Gebo
    Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    J Acquir Immune Defic Syndr 36:1028-33. 2004
    ..The absolute CD4 count is the more important measure of immune status and is preferred over the CD4% for making treatment decisions in HIV-infected adults...
  36. ncbi Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy
    Richard E Nettles
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Clin Infect Dis 39:1030-7. 2004
    ....
  37. ncbi Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis
    Jose R Arribas
    Internal Medicine Service, Hospital de La Paz, Madrid, Spain
    J Acquir Immune Defic Syndr 47:74-8. 2008
    ..As antiretroviral regimens for the treatment of HIV infection improve, trials providing data on long-term follow-up are increasingly important...
  38. ncbi Renal safety of tenofovir disoproxil fumarate
    Paul E Sax
    AIDS Read 17:90-2, 99-104, C3. 2007
    ..We present a review of the renal safety of tenofovir and provide a brief summary of the clinical implications of these data...
  39. ncbi Relationship between drug resistance and HIV-1 disease progression or death in patients undergoing resistance testing
    Gregory M Lucas
    Johns Hopkins University, Baltimore, Maryland, USA
    AIDS 18:1539-48. 2004
    ....
  40. ncbi The M184V mutation: what it does, how to prevent it, and what to do with it when it's there
    Joel E Gallant
    Division of Infectious Diseases at Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    AIDS Read 16:556-9. 2006
    ..While it is always better not to have any drug resistance so that 3TC and FTC are available as active antiretroviral agents, it is important to take advantage of the beneficial effects of the M184V mutation when it is present...
  41. ncbi Report from San Francisco: The 11th Conference on Retroviruses and Opportunistic Infections (CROI). Antiretroviral therapy: the naïve patient
    Joel E Gallant
    Hopkins HIV Rep 16:1-4. 2004
  42. ncbi Drug resistance after failure of initial antiretroviral therapy in resource-limited countries
    Joel E Gallant
    Clin Infect Dis 44:453-5. 2007
  43. ncbi AACTG A5095, Trizivir, and the role of all-nucleoside regimens: an editorial
    Joel E Gallant
    Hopkins HIV Rep 15:1-2. 2003
  44. ncbi Drug resistance and treatment of experienced patients
    Joel E Gallant
    Hopkins HIV Rep 15:8-9. 2003
  45. ncbi A case of seronegative HIV-1 infection
    Adam M Spivak
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    J Infect Dis 201:341-5. 2010
    ..Lack of an antibody response to HIV-1 is rare and appears to be due to a defect in HIV-1-specific immunity rather than infection with attenuated virus...
  46. ncbi XV International AIDS Conference in Bangkok: antiretroviral therapy
    Joel E Gallant
    Hopkins HIV Rep 16:1-6. 2004
  47. ncbi Prognostic value of plasma HIV RNA among highly active antiretroviral therapy users
    Patrick M Tarwater
    School of Public Health, University of Texas Health Science Center, 1100 N. Stanton, Suite 110, El Paso, TX 79902, USA
    AIDS 18:2419-23. 2004
    ....
  48. ncbi Antiretroviral rounds. Is that "one pill" treatment enough?
    Joel E Gallant
    AIDS Clin Care 20:53-4. 2008
  49. ncbi Tolerability and efficacy of PI versus NNRTI-based regimens in subjects receiving HAART during acute or early HIV infection
    Linda G Apuzzo
    Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
    J Acquir Immune Defic Syndr 50:267-75. 2009
    ..Little is known about modifications to highly active antiretroviral therapy (HAART) initiated during acute or early HIV infection...
  50. ncbi When and how to use tipranavir and darunavir
    Christopher J Hoffman
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    AIDS Read 17:194-8, 201. 2007
  51. ncbi When to start antiretroviral therapy: a swinging pendulum?
    Joel E Gallant
    The Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Top HIV Med 16:82-8. 2008
    ..This article summarizes a presentation on when to initiate antiretroviral therapy made by Joel E. Gallant, MD, MPH, at an International AIDS Society-USA Continuing Medical Education course in New York in October 2007...
  52. ncbi HIV type 1 RNA level as a clinical indicator of renal pathology in HIV-infected patients
    Michelle Estrella
    Department of Medicine, Division of Nephrology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA
    Clin Infect Dis 43:377-80. 2006
    ..Hypertensive vascular disease surpassed HIV-associated nephropathy as the most common renal pathological finding among the entire cohort. HIV-1 RNA level did not correlate with renal survival...
  53. ncbi Report from Los Angeles: the 14th Conference on Retroviruses and Opportunistic Infections (CROI). Management of treatment-naïve patients
    Joel E Gallant
    Hopkins HIV Rep 19:1-3, 12. 2007
  54. ncbi Loss of HIV-1-specific immunity during treatment interruption in 2 chronically infected patients
    Joel N Blankson
    JAMA 288:162-4. 2002
  55. ncbi Current management challenges in HIV: antiretroviral resistance
    Daniel R Kuritzkes
    Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts, USA
    AIDS Read 13:133-5, 138-42. 2003
    ..However, there is a need for additional trials to better define the role resistance testing may play in developing management approaches to mitigate or minimize emergence of resistant HIV...
  56. ncbi Making sense of blips
    Joel E Gallant
    J Infect Dis 196:1729-31. 2007
  57. ncbi Antiretroviral rounds. Virologic failure: true or false?
    Joel E Gallant
    AIDS Clin Care 17:84-5. 2005
  58. ncbi Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study
    Hassane Izzedine
    Department of Nephrology, Pitie Salpetriere Hospital, 47 83 boulevard de l Hopital, 75013 Paris, France
    Nephrol Dial Transplant 20:743-6. 2005
    ..However, controlled data are sparse on the long-term renal tolerability of TDF at the currently approved daily dose of 300 mg in treatment-naive HIV-infected patients...
  59. ncbi Antiretroviral update from the 46th ICAAC
    Joel E Gallant
    Hopkins HIV Rep 19:1-3, 12. 2007
  60. ncbi Prolonged treatment interruption after immunologic response to highly active antiretroviral therapy
    Patrick M Tarwater
    University of Texas Health Science Center, School of Public Health, Houston, Texas, USA
    Clin Infect Dis 37:1541-8. 2003
    ..Our results have implications for this TI strategy: there may be a subset of patients who can safely discontinue therapy for prolonged periods of time...
  61. ncbi A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy
    Jacob P Lalezari
    Quest Clinical Research, San Francisco, CA 94115, USA
    AIDS 17:691-8. 2003
    ..Secondary objectives included the determination of enfuvirtide pharmacokinetics and antiviral activity and the immunological response to the enfuvirtide-containing regimen...
  62. ncbi Treatment of naïve patients: update from the 12th CROI
    Joel E Gallant
    Hopkins HIV Rep 17:4-5. 2005
  63. ncbi Antiretroviral news from the 41st ICAAC
    Joel E Gallant
    Hopkins HIV Rep 14:1-5. 2002
  64. ncbi Risk factors for Kaposi's sarcoma among HHV-8 seropositive homosexual men with AIDS
    Eric Nawar
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA
    Int J Cancer 115:296-300. 2005
    ..Alternatively, our findings may reflect factors protective against KS in individuals infected with HHV-8. Future research should focus on identifying practical measures for countering KS that do not increase the risk of other diseases...
  65. ncbi Current perspectives on the nucleoside/nucleotide components of combination antiretroviral therapy
    Joel E Gallant
    Baltimore, MD, USA
    J Acquir Immune Defic Syndr 37:S1. 2004
  66. ncbi High frequency of highly active antiretroviral therapy modifications in patients with acute or early human immunodeficiency virus infection
    Beulah P Sabundayo
    Department of Medicine, School of Medicine, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, 21287, USA
    Pharmacotherapy 26:674-81. 2006
    ....
  67. ncbi Association between use of HMG CoA reductase inhibitors and mortality in HIV-infected patients
    Richard D Moore
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America
    PLoS ONE 6:e21843. 2011
    ..The HMG-coenzyme A reductase inhibitors (statins) inhibit several pro-inflammatory processes and suppress immune activation, and are a logical therapy to assess for a possible salutary effect on HIV disease progression and outcomes...
  68. ncbi HIV/AIDS: the management of treatment-experienced HIV-infected patients: new drugs and drug combinations
    Lucy E Wilson
    Division of Infectious Diseases, Johns Hopkins School of Medicine, 1830 E Monument Street, Baltimore, MD 21287, USA
    Clin Infect Dis 48:214-21. 2009
    ..This review discusses the use of recently approved antiretroviral agents in the management of HIV infection in treatment-experienced patients...
  69. ncbi Editorial comment: strategies for success--a return to "hit early"?
    Joel E Gallant
    AIDS Read 14:662-3. 2004
  70. ncbi Antiretroviral news from the Chicago: the 43rd ICAAC
    Joel E Gallant
    Hopkins HIV Rep 15:1-4. 2003
  71. ncbi Editorial comment: predictors of response--updating the traditional list
    Joel E Gallant
    AIDS Read 16:432-3. 2006
  72. ncbi Report from Boston: the 10th Conference on Retroviruses and Opportunistic Infections (CROI)
    Joel E Gallant
    Hopkins HIV Rep 15:1-2, 11. 2003
  73. ncbi Drug resistance and the treatment of experienced patients
    Joel E Gallant
    Hopkins HIV Rep 14:1, 5-7, 16. 2002
  74. ncbi Antiretroviral therapy update from the 44th ICAAC
    Joel E Gallant
    Hopkins HIV Rep 17:1-3, 7. 2005
  75. ncbi Editorial comment: treating the experienced patient--when and how to use new agents
    Joel E Gallant
    AIDS Read 16:274-5. 2006
  76. ncbi HIV-1 DNA is detected in bone marrow populations containing CD4+ T cells but is not found in purified CD34+ hematopoietic progenitor cells in most patients on antiretroviral therapy
    Christine M Durand
    Department of Medicine, The Sidney Kimmel CancerCenter, USA
    J Infect Dis 205:1014-8. 2012
    ..We did not find HIV-1 DNA in highly purified CD34(+) populations using either a sensitive real-time polymerase chain reaction assay or a coculture assay for replication-competent HIV-1...
  77. ncbi Mycobacterium avium complex immune reconstitution inflammatory syndrome: long term outcomes
    James Riddell
    Department of Internal Medicine, Division of Infectious Diseases, University of Michigan Health System, Ann Arbor, Michigan, USA
    J Transl Med 5:50. 2007
    ..To describe long term outcomes of Mycobacterium avium complex (MAC) immune reconstitution inflammatory syndrome (IRIS)...
  78. ncbi Initial regimens for the treatment-naive patient: current understanding and practice
    Christopher J Hoffmann
    Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    AIDS Read 18:326-30, 336-8. 2008
  79. ncbi Report from ICAAC: new drugs and antiretroviral therapy for naïve patients
    Joel E Gallant
    Hopkins HIV Rep 14:1-3, 7. 2002
  80. ncbi Human immunodeficiency virus infection and hospital mortality in acute lung injury patients
    Pedro A Mendez-Tellez
    Department of Anesthesiology and Critical Care Medicine, Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, MD, USA
    Crit Care Med 38:1530-5. 2010
    ..To evaluate the impact of human immunodeficiency virus infection on hospital mortality in patients with acute lung injury and to evaluate predictors of mortality among acute lung injury patients with human immunodeficiency virus...
  81. ncbi Current status of antiretroviral treatment interruption and intermittent therapy strategies
    Joel E Gallant
    Division of Infectious Diseases, Johns Hopkins AIDS Service, Baltimore, Maryland, USA
    MedGenMed 4:19. 2002
  82. ncbi Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda
    Steven J Reynolds
    Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
    AIDS Res Hum Retroviruses 28:1739-44. 2012
    ..PI resistance was not detected in individuals failing second-line ART. Surveillance for transmitted and acquired drug resistance remains a priority for scale-up of ART...